BioNTech (BNTX) FY 2025 Conference January 14, 2025 12:00 PM ET Speaker0 Great. Good morning, everyone. We're going get started. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing the forty third Annual Healthcare Conference today with We're going to hear a presentation from the company and then go into Q and A. If you're in the audience and you want to ask questions, someone will bring you a microphone or you can send them to me up here through the portal. But with that, let me pa ...

根据弗若斯特沙利文的资料， 觅瑞 是开发及商业化用于癌症及其他疾病早期检测 的、精准的、无 创的、可负担的、基于血液的miRNA检测试剂盒的先驱者与领导者 ； 根据弗若斯特沙利文的资料， 觅瑞 是全球为数不多的已获得分子癌症筛查行业IVD产品监管批准的公司之一，同时也是全球范围 内首家且唯一一家获得分子胃癌筛查IVD产品监管批准的公司。 今年上半年，核心产品GASTROClear的毛利率超80%。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，Mirxes Holding Company Limited（以下简称"觅瑞"）于11月4日更新招股 书，继续推进港交所主板上市进程，中金公司和建银国际担任联席保荐人。 成立于2014年的觅瑞作为一家起源于新加坡的微小核糖核酸("miRNA")技术公司，专注于在全球范 围内普及疾病筛查诊断解决方案。 截至2024年10月31日，觅瑞拥有一种核心产品(即GASTROClear)、两种其他商业化产品(即 LungClear及Fortitude)以及六种处于临床前阶段的候选产品。 其中，觅瑞的核心产品GASTROC ...

Intensity Therapeutics (INTS) Conference April 09, 2024 10:00 AM ET Speaker0 K. Good afternoon, everyone. We're gonna start our next presentation. I'd like to introduce Louis Bender with Intensity Therapeutics, welcome. Speaker1 Well thank you very much and I appreciate everybody's round of applause now. So thank you, I'm happy to be here, good afternoon. I'm gonna talk about cancer and I'm gonna talk about something that I think is very exciting, a new weapon in the war on cancer. My background is I'm a ch ...